Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.45 |
| ▸ | PPARA | Q07869 | 8/20 | 0.41 |
| ▸ | PPARG | P37231 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5034523 | 0.94 | HPGD (0.46) | PPARAPPARGMAPTALDH1A1NPC1 | |
| SCHEMBL5031926 | 0.90 | PPARA (0.44) | PPARAPPARGMAPTNPC1HPGD | |
| SCHEMBL5034527 | 0.88 | PPARA (0.47) | PPARAPPARGMEN1KMT2AMAPT | |
| SCHEMBL5037102 | 0.84 | CYP1A2 (0.45) | CYP1A2CYP3A4PPARAMEN1KMT2A | |
| SCHEMBL6427465 | 0.83 | PPARA (0.39) | PPARAPPARGMAPTALDH1A1HPGD | |
| SCHEMBL5034516 | 0.81 | PPARA (0.46) | PPARAPPARGMEN1KMT2AMAPT | |
| SCHEMBL5031873 | 0.78 | POLB (0.53) | CYP1A2CYP3A4MEN1KMT2AMAPT | |
| SCHEMBL5037183 | 0.77 | NPC1 (0.45) | PPARAPPARGMAPTALDH1A1NPC1 | |
| SCHEMBL5031956 | 0.76 | PPARA (0.49) | PPARAPPARGMAPTNPC1HPGD | |
| SCHEMBL5032982 | 0.76 | PPARA (0.49) | PPARAPPARGNPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014833-A1 | Cyclic compound and ppar agonist | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1452521-A1 | CYCLIC COMPOUND AND PPAR AGONIST | Eisai Co., Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014833-A1 | Cyclic compound and ppar agonist | PPARA, PPARG, PPARD | CYP1A2 493/4885CYP3A4 1017/4885PPARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.